The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults ...

Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) ...

Matching-adjusted indirect comparison methodology was utilized to compare ibrutinib arms across the ALPINE and ELEVATE-RR trials. In each study, ibrutinib was used as the comparator for a ...

In " Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels explore how ...